Cargando…

Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy

Currently, the nutraceutical approach to treat dyslipidaemia is increasing in use, and in many cases is used by physicians as the first choice in the treatment of patients with borderline values. Nutraceuticals represent an excellent opportunity to treat the preliminary conditions not yet showing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Colletti, Alessandro, Fratter, Andrea, Pellizzato, Marzia, Cravotto, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696395/
https://www.ncbi.nlm.nih.gov/pubmed/36432457
http://dx.doi.org/10.3390/nu14224769
_version_ 1784838307189882880
author Colletti, Alessandro
Fratter, Andrea
Pellizzato, Marzia
Cravotto, Giancarlo
author_facet Colletti, Alessandro
Fratter, Andrea
Pellizzato, Marzia
Cravotto, Giancarlo
author_sort Colletti, Alessandro
collection PubMed
description Currently, the nutraceutical approach to treat dyslipidaemia is increasing in use, and in many cases is used by physicians as the first choice in the treatment of patients with borderline values. Nutraceuticals represent an excellent opportunity to treat the preliminary conditions not yet showing the pathological signs of dyslipidaemia. Their general safety, the patient’s confidence, the convincing proof of efficacy and the reasonable costs prompted the market of new preparations. Despite this premise, many nutraceutical products are poorly formulated and do not meet the minimum requirements to ensure efficacy in normalizing blood lipid profiles, promoting cardiovascular protection, and normalizing disorders of glycemic metabolism. In this context, bioaccessibility and bioavailability of the active compounds is a crucial issue. Little attention is paid to the proper formulations needed to improve the overall bioavailability of the active molecules. According to these data, many products prove to be insufficient to ensure full enteric absorption. The present review analysed the literature in the field of nutraceuticals for the treatment of dyslipidemia, focusing on resveratrol, red yeast rice, berberine, and plant sterols, which are among the nutraceuticals with the greatest formulation problems, highlighting bioavailability and the most suitable formulations.
format Online
Article
Text
id pubmed-9696395
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96963952022-11-26 Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy Colletti, Alessandro Fratter, Andrea Pellizzato, Marzia Cravotto, Giancarlo Nutrients Review Currently, the nutraceutical approach to treat dyslipidaemia is increasing in use, and in many cases is used by physicians as the first choice in the treatment of patients with borderline values. Nutraceuticals represent an excellent opportunity to treat the preliminary conditions not yet showing the pathological signs of dyslipidaemia. Their general safety, the patient’s confidence, the convincing proof of efficacy and the reasonable costs prompted the market of new preparations. Despite this premise, many nutraceutical products are poorly formulated and do not meet the minimum requirements to ensure efficacy in normalizing blood lipid profiles, promoting cardiovascular protection, and normalizing disorders of glycemic metabolism. In this context, bioaccessibility and bioavailability of the active compounds is a crucial issue. Little attention is paid to the proper formulations needed to improve the overall bioavailability of the active molecules. According to these data, many products prove to be insufficient to ensure full enteric absorption. The present review analysed the literature in the field of nutraceuticals for the treatment of dyslipidemia, focusing on resveratrol, red yeast rice, berberine, and plant sterols, which are among the nutraceuticals with the greatest formulation problems, highlighting bioavailability and the most suitable formulations. MDPI 2022-11-11 /pmc/articles/PMC9696395/ /pubmed/36432457 http://dx.doi.org/10.3390/nu14224769 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Colletti, Alessandro
Fratter, Andrea
Pellizzato, Marzia
Cravotto, Giancarlo
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title_full Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title_fullStr Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title_full_unstemmed Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title_short Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy
title_sort nutraceutical approaches to dyslipidaemia: the main formulative issues preventing efficacy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696395/
https://www.ncbi.nlm.nih.gov/pubmed/36432457
http://dx.doi.org/10.3390/nu14224769
work_keys_str_mv AT collettialessandro nutraceuticalapproachestodyslipidaemiathemainformulativeissuespreventingefficacy
AT fratterandrea nutraceuticalapproachestodyslipidaemiathemainformulativeissuespreventingefficacy
AT pellizzatomarzia nutraceuticalapproachestodyslipidaemiathemainformulativeissuespreventingefficacy
AT cravottogiancarlo nutraceuticalapproachestodyslipidaemiathemainformulativeissuespreventingefficacy